Reporting Clinical Data from a First-in-Class Plasmacytoid Dendritic Cell Line Vaccine in Patients with Metastatic NSCLC

Time: 10:00 am
day: Day Two


• Understanding the characteristics and applications of the PDC*vac technology as a

novel allogeneic cancer vaccine

• Reviewing early safety, tolerability, and immunogenicity findings from this phase one trial

• Discussing initial signs of clinical activity associated with the vaccine in NSCLC patients